Peter S Kim has bought TRDA on 4 days since Apr 2024

Kim Peter S. is an individual and serves as a Director at Entrada Therapeutics, Inc. (NASDAQ: TRDA), where he also provides strategic advisory support.( He joined Entrada’s board in January 2021, and the company has described him as a pioneering scientist with more than 30 years of experience spanning academia and the biopharmaceutical industry.(

Dr. Kim is the Virginia & D.K. Ludwig Professor of Biochemistry at Stanford University, an Institute Scholar at Stanford ChEM-H, and Lead Investigator of the Infectious Disease Initiative at the Chan Zuckerberg Biohub.( Before Stanford, he was President of Merck Research Laboratories from 2003 to 2013, where he oversaw global drug and vaccine R&D and the approval of more than 20 new medicines and vaccines.( Earlier in his career, he was a professor at MIT and a member of the Whitehead Institute, and his scientific achievements led to election to several major academies, including the National Academy of Sciences, the National Academy of Medicine, and the National Academy of Engineering.(

Written by Perplexity from public sources.